抽象的な
Pharmacokinetic-Led Guidance for Patients with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor with Nirmatrelvir-Ritonavir
Duarte Afonso
Cystic fibrosis transmembrane conductance controller balancing treatments, including elexacaftor-tezacaftor-ivacaftor, are essentially wiped out through cytochrome P450 (CYP) 3A-intervened digestion. This makes a 56restorative test to the treatment of Covid illness 2019 (COVID-19) with nirmatrelvir-ritonavir in individuals with Cystic Fibrosis (CF) because of the potential for huge medication drug communications (DDIs). Be that as it may, the populace with CF is more in danger of difficult disease following COVID-19 contamination and subsequently it is vital to deal with the DDI risk and give treatment choices.
免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。